Vincent Bourgeois

602 total citations
19 papers, 127 citations indexed

About

Vincent Bourgeois is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Vincent Bourgeois has authored 19 papers receiving a total of 127 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Vincent Bourgeois's work include Colorectal Cancer Treatments and Studies (10 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Treatment and Pharmacology (3 papers). Vincent Bourgeois is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Treatment and Pharmacology (3 papers). Vincent Bourgeois collaborates with scholars based in France, Italy and Israel. Vincent Bourgeois's co-authors include Myriam Delhaye, Thierry Velu, Jacques Devière, Michel Cremer, Jasmine Parma, Pascale Cochaux, Jean‐Luc Van Laethem, Christophe Desauw, Capucine Baldini and Olivier Bouché and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Cardiology and Annals of Oncology.

In The Last Decade

Vincent Bourgeois

14 papers receiving 125 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vincent Bourgeois France 5 100 80 57 24 14 19 127
Daniel José Szor Brazil 8 86 0.9× 96 1.2× 126 2.2× 19 0.8× 16 1.1× 26 217
Ross M. Beckman United States 8 135 1.4× 104 1.3× 43 0.8× 37 1.5× 19 1.4× 12 181
Teresa Perra Italy 6 64 0.6× 77 1.0× 49 0.9× 14 0.6× 15 1.1× 12 123
Gyoung Tae Noh South Korea 11 201 2.0× 152 1.9× 59 1.0× 28 1.2× 22 1.6× 32 256
Helwig Wundsam Austria 9 142 1.4× 159 2.0× 52 0.9× 37 1.5× 10 0.7× 27 212
Najib Lamfichekh France 7 120 1.2× 110 1.4× 56 1.0× 13 0.5× 11 0.8× 7 171
Giuseppe Palomba Italy 7 141 1.4× 48 0.6× 130 2.3× 17 0.7× 27 1.9× 28 211
Irene Pecora Italy 9 130 1.3× 75 0.9× 99 1.7× 32 1.3× 32 2.3× 24 207
Pauline Duconseil France 7 156 1.6× 134 1.7× 87 1.5× 14 0.6× 18 1.3× 15 191
Fabio Casciani Italy 8 145 1.4× 135 1.7× 60 1.1× 16 0.7× 7 0.5× 41 193

Countries citing papers authored by Vincent Bourgeois

Since Specialization
Citations

This map shows the geographic impact of Vincent Bourgeois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Bourgeois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Bourgeois more than expected).

Fields of papers citing papers by Vincent Bourgeois

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Bourgeois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Bourgeois. The network helps show where Vincent Bourgeois may publish in the future.

Co-authorship network of co-authors of Vincent Bourgeois

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Bourgeois. A scholar is included among the top collaborators of Vincent Bourgeois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Bourgeois. Vincent Bourgeois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Merle, Philippe, Jean-Marie Péron, Karine Le Malicot, et al.. (2024). Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 42(16_suppl). e16195–e16195. 1 indexed citations
3.
4.
5.
Martin, E., Karine Le Malicot, Catherine Guérin‐Charbonnel, et al.. (2024). How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology. Current Oncology. 31(6). 3513–3528.
6.
7.
8.
Adenis, Antoine, Méher Ben Abdelghani, Vincent Bourgeois, et al.. (2023). Early palliative care for patients with metastatic upper gastrointestinal cancers: A survival analysis of the EPIC randomized trial.. Journal of Clinical Oncology. 41(16_suppl). 12102–12102. 1 indexed citations
9.
Boccaccino, Alessandra, Claire Gallois, Maria Antista, et al.. (2022). Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. European Journal of Cancer. 168. 34–40. 8 indexed citations
10.
Legoux, Jean-Louis, Roger Faroux, Nicolas M. Barrière, et al.. (2022). Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.. Journal of Clinical Oncology. 40(16_suppl). 3555–3555. 1 indexed citations
11.
Chibaudel, Benoist, Louis-Marie Dourthe, Thierry André, et al.. (2022). STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.. Journal of Clinical Oncology. 40(16_suppl). 3504–3504. 7 indexed citations
12.
Boccaccino, Alessandra, Filippo Pietrantonio, Lorenzo Pilla, et al.. (2021). 440P Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients. Annals of Oncology. 32. S554–S554.
13.
Phelip, Jean–Marc, Jérôme Desrame, Julien Edeline, et al.. (2020). 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial. Annals of Oncology. 31. S260–S261. 11 indexed citations
14.
Legoux, Jean-Louis, Roger Faroux, Nicolas M. Barrière, et al.. (2020). 444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers. Annals of Oncology. 31. S430–S431. 1 indexed citations
15.
Baldini, Capucine, Anne Escande, Olivier Bouché, et al.. (2016). Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. Pancreatology. 17(1). 146–149. 24 indexed citations
16.
Zerimech, Farid, Fabienne Escande, Antoine Adenis, et al.. (2016). Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.. PubMed. 36(8). 4233–6. 1 indexed citations
17.
Baldini, Capucine, Anne Escande, Olivier Bouché, et al.. (2015). 1326 Folfirinage: Tolerance and efficacy of folfirinox in elderly patients with advanced pancreatic adenocarcinoma. European Journal of Cancer. 51. S196–S196. 2 indexed citations
18.
Laethem, Jean‐Luc Van, Vincent Bourgeois, Jasmine Parma, et al.. (1998). Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointestinal Endoscopy. 47(6). 479–485. 64 indexed citations
19.
Lipiecki, Janusz, Jean C. Maublant, Bernard Citron, et al.. (1997). Comparable Uptake of Thallium-201 and Technetium-99m MIBI in Hibernating and “Maimed” Myocardium. The American Journal of Cardiology. 80(7). 940–943. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel José Szor Breakdown of academic impact, for papers by Ross M. Beckman Breakdown of academic impact, for papers by Teresa Perra Breakdown of academic impact, for papers by Gyoung Tae Noh Breakdown of academic impact, for papers by Helwig Wundsam Breakdown of academic impact, for papers by Najib Lamfichekh Breakdown of academic impact, for papers by Giuseppe Palomba Breakdown of academic impact, for papers by Irene Pecora Breakdown of academic impact, for papers by Pauline Duconseil Breakdown of academic impact, for papers by Fabio Casciani
Rankless by CCL
2026